Search - tctmd.com

Displaying 281 - 300 of 375

Sort: Relevancy | Date

Presentation

Antiplatelet Therapy Duration Following BMS or DES: The DAPT Randomized Clinical Trial

Presenter: D. J. Kereiakes

March 24, 2015

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Presentation

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Presenter: Martine Gilard

March 10, 2015

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

Presentation

Association Between the Use of Fondaparinux vs LMWH and Clinical Outcomes in NSTEMI Patients

Presenter: Karolina Szummer

February 19, 2015

Presentation

Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Stable CAD

Presenter: M. Hanon

September 30, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Pascal Vranckx

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Matthew J. Price

September 17, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Daniel I. Simon

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Thomas D. Stuckey

September 17, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Neal S. Kleiman

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Frederick Kushner

September 17, 2014

Presentation TCT 2014

Adjunctive Pharmacotherapy During and After TAVR: BRAVO 3 and Beyond

Presenter: George D. Dangas

September 16, 2014

Presentation TCT 2014

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

Presenter: Fausto Feres

September 16, 2014

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Presentation TCT 2014

TCT 12: The Impact of Platelet Receptor Gene Polymorphisms on Clinical Outcomes in Patients with ST-Elevation Myocardial Infarction After Percutaneous Coronary Intervention

Presenter: Ori Ben-Yehuda, Matthew T. Roe, David J. Moliterno, Jia-Hui Zhang

September 15, 2014

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

Presentation TCT 2014

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff

September 15, 2014

Presentation TCT 2014

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

Presenter: Roxana Mehran, Harvey D. White, Yaling Han

September 15, 2014

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Advertisement

Antiplatelet Therapy Duration Following BMS or DES: The DAPT Randomized Clinical Trial

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Association Between the Use of Fondaparinux vs LMWH and Clinical Outcomes in NSTEMI Patients

Incidence, Source, Determinants, and Prognostic Impact of Major Bleeding in Stable CAD

Thoughtful Insights

Case Presentation

Thoughtful Insights

Case Presentation

Thoughtful Insights

Case Presentation

Adjunctive Pharmacotherapy During and After TAVR: BRAVO 3 and Beyond

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

TCT 12: The Impact of Platelet Receptor Gene Polymorphisms on Clinical Outcomes in Patients with ST-Elevation Myocardial Infarction After Percutaneous Coronary Intervention

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content